“CKD substantially increases the risk of CV events, with a graded relationship between
advancing stages of CKD and rates of fatal and non-fatal MI and the probablity of death …

AIM: The 2018 New Zealand Consensus Statement on cardiovascular disease (CVD) risk
assessment and management recommends the use of aspirin in people aged less than 70 …

Low-dose aspirin (acetylsalicylic acid [ASA]; 75 to 100 mg/d) is widely used in the prevention
of cardiovascular (CV) events based on the results of large-scale studies supporting a …

AIM: To assess benefit versus harm of aspirin for cardiovascular disease (CVD) primary
prevention by age group, gender and risk category and to interpret these results in light of …

Background Current evidence and practice guidelines do not recommend aspirin for primary
prevention of cardiovascular disease (CVD). Insufficient all‐cause mortality benefits …

Introduction: Low-dose aspirin protects against ischemic cardio-and cerebrovascular
disease (CVD/CeVD) and colorectal cancer yet may be associated with a small increased …

Methods All trials from the previous 2009 USPSTF guideline on the use of aspirin for primary
CVD prevention (minimum of 75 mg every other day for 1 year or more) in adults aged 40 or …

Patients who have had cardiovascular disease and stroke are treated with aspirin to reduce
their subsequent risk of vascular events or death and thereby to increase the length and …

Background: Whether the benefits of aspirin for the primary prevention of cardiovascular
disease (CVD) outweigh its bleeding harms in some patients is unclear. Objective: To …

In view of current evidence, we do not recommend routinely using aspirin for primary
prevention of cardiovascular disease, even in patients with diabetes mellitus. The decision …